These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
69 related articles for article (PubMed ID: 2624510)
21. Phase I-II trial of high-dose epirubicin in patients with lymphoma. Case DC; Gams R; Ervin TJ; Boyd MA; Oldham FB Cancer Res; 1987 Dec; 47(23):6393-6. PubMed ID: 3479245 [TBL] [Abstract][Full Text] [Related]
22. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Cardinale D; Colombo A; Sandri MT; Lamantia G; Colombo N; Civelli M; Martinelli G; Veglia F; Fiorentini C; Cipolla CM Circulation; 2006 Dec; 114(23):2474-81. PubMed ID: 17101852 [TBL] [Abstract][Full Text] [Related]
23. First-line intra-arterial chemotherapy (IAC) with epirubicin and mitoxantrone in locally advanced breast cancer. Fiorentini G; Tsetis D; Bernardeschi P; Varveris C; Rossi S; Kalogeraki A; Athanasakis E; Dentico P; Kanellos P; Biancalani M; Almarashdah S; Zacharioudakis G; Saridaki Z; Chalkiadakis G; Xynos E; Zoras O Anticancer Res; 2003; 23(5b):4339-45. PubMed ID: 14666649 [TBL] [Abstract][Full Text] [Related]
24. [Cardiotoxicity of mitoxantrone]. Okuma K; Ariyoshi Y; Ota K Gan To Kagaku Ryoho; 1986 Oct; 13(10):3040-5. PubMed ID: 3464231 [TBL] [Abstract][Full Text] [Related]
25. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Le Page E; Leray E; Edan G; Mult Scler; 2011 Jul; 17(7):867-75. PubMed ID: 21325016 [TBL] [Abstract][Full Text] [Related]
26. [Mitoxantrone - an anthraquinone antibiotic with antitumor activity applied for the treatment of multiple sclerosis]. Szwed M Postepy Hig Med Dosw (Online); 2014 Feb; 68():198-208. PubMed ID: 24662788 [TBL] [Abstract][Full Text] [Related]
27. Radionuclide ejection fraction in doxorubicin cardiotoxicity. Morgan GW; McIlveen BM; Freedman A; Murray IP Cancer Treat Rep; 1981; 65(7-8):629-38. PubMed ID: 7248982 [TBL] [Abstract][Full Text] [Related]
28. Amsacrine cardiotoxicity: assessment of ventricular function by radionuclide angiography. Vorobiof DA; Iturralde M; Falkson G Cancer Treat Rep; 1983 Dec; 67(12):1115-7. PubMed ID: 6689141 [TBL] [Abstract][Full Text] [Related]
29. Blood-pool radionuclide angiography in patients with a Novacor left ventricular assist device. Athanasoulis T; Sekela ME; Noon GP; Young JB; Verani MS J Nucl Med; 1991 Feb; 32(2):255-8. PubMed ID: 1992029 [TBL] [Abstract][Full Text] [Related]
30. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Feola M; Garrone O; Occelli M; Francini A; Biggi A; Visconti G; Albrile F; Bobbio M; Merlano M Int J Cardiol; 2011 Apr; 148(2):194-8. PubMed ID: 19945181 [TBL] [Abstract][Full Text] [Related]
31. A dose-finding study of epirubicin in combination with paclitaxel in the treatment of advanced breast cancer. Conte PF; Michelotti A; Baldini E; Salvadori B; Gennari A; Da Prato M; Tibaldi C; Salzano E; Gentile A Semin Oncol; 1996 Oct; 23(5 Suppl 11):28-31. PubMed ID: 8893896 [TBL] [Abstract][Full Text] [Related]
32. Reversible Cardiomyopathy After Epirubicin Administration. Koitabashi N; Ohyama Y; Tateno R; Arai M; Rokutanda N; Horiguchi J; Kurabayashi M Int Heart J; 2015; 56(4):466-8. PubMed ID: 26104177 [TBL] [Abstract][Full Text] [Related]
33. Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group. Bonneterre J; Roché H; Kerbrat P; Fumoleau P; Goudier MJ; Fargeot P; Montcuquet P; Clavère P; Barats JC; Monnier A; Veyret C; Datchary J; Van Praagh I; Chapelle-Marcillac I J Clin Oncol; 2004 Aug; 22(15):3070-9. PubMed ID: 15284257 [TBL] [Abstract][Full Text] [Related]
34. Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers. Mantovani G; Madeddu C; Cadeddu C; Dessì M; Piras A; Massa E; Serpe R; Antoni G; Mercuro G Oncologist; 2008 Dec; 13(12):1296-305. PubMed ID: 19060235 [TBL] [Abstract][Full Text] [Related]
35. Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy. Tsai HR; Gjesdal O; Wethal T; Haugaa KH; Fosså A; Fosså SD; Edvardsen T Am J Cardiol; 2011 Feb; 107(3):472-7. PubMed ID: 21257017 [TBL] [Abstract][Full Text] [Related]
36. [On the problem of the cardiotoxicity of epirubicin-cisplatin]. Lechner W; Zechmann W; Mayr P; Reider W; Marth C Zentralbl Gynakol; 1988; 110(7):429-32. PubMed ID: 3164959 [TBL] [Abstract][Full Text] [Related]
37. Correlation of right and left ventricular ejection fraction and volume measurements. Benedetto AR; Nusynowitz ML J Nucl Med; 1988 Jun; 29(6):1114-7. PubMed ID: 3373319 [TBL] [Abstract][Full Text] [Related]
38. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Seymour L; Bramwell V; Moran LA Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762 [TBL] [Abstract][Full Text] [Related]
39. Assessment of early epirubicin cardiotoxicity in women with breast cancer. Sobić-Saranović D; Pavlović S; Susnjar S; Neskovi c-Konstantinović Z; Jelić S Anticancer Res; 1997; 17(5B):3889-91. PubMed ID: 9427798 [TBL] [Abstract][Full Text] [Related]
40. Selective right ventricular dysfunction following doxorubicin therapy. Sperber AD; Cantor AA; Biran H; Keynan A Isr J Med Sci; 1987 Aug; 23(8):896-9. PubMed ID: 3679793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]